secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2026-06-01T23:07:35+00:00
Accession:  0001674930-26-000028
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent Genetics reports encouraging Phase 2 data for FID-007 in HNSCC at ASCO 2026
--------------------------------------------------------------------------------

- FID-007 + cetuximab showed 61.9% objective response rate in PD-1 resistant R/M HNSCC.
- Median progression-free survival 6.7 months; median duration of response 7.4 months.
- One-year overall survival rate 63.4% in target population.
- Phase 3 study is planned based on these results.
- Data cutoff April 16, 2026; presentation at ASCO 2026 Rapid Oral Abstract Session.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000167493026000028/0001674930-26-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000167493026000028/flgt-20260601.htm
  HTML page:      https://secwatch.observer/filing/0001674930-26-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer